Clinical trial
A Randomized, Double-blind, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Two Different Dose Groups of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Compared to the Placebo Control Group
NCT05424887 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Two Different Dose Groups of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Compared to the Placebo Control Group
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2022
- Completion date
- October 31, 2024
- Enrollment
- 105 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.